Business Wire

Pharnext to Present Latest Scientific Data on its Two Lead Assets at Several International Scientific Conferences

Jaa

Regulatory News:

Pharnext SA (FR0011191287 - ALPHA) (Paris:ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced its upcoming participation in five international scientific conferences in June and July 2018 throughout Europe and the United States.

Pharnext will share the latest scientific and clinical data regarding PXT3003, a drug candidate which is currently being evaluated in an ongoing international pivotal Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A. Pharnext will also illustrate the benefits of its disruptive R&D approach PLEOTHERAPY™ in developing drug combinations, and discuss the Company’s Phase 2 trial of PXT864 for the treatment of Alzheimer’s disease.

The company will attend the following events:

European Academy of Neurology (EAN) congress
June 16-18, 2018 in Lisbon, Portugal

Two ePosters (oral communications)

#EPR1170  

A multicenter, double-blind, placebo-controlled, pivotal phase III study (PLEO-CMT) of a
fixed combination of baclofen, naltrexone and sorbitol (PXT3003) for Charcot-Marie-Tooth
Disease Type 1A (CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR122 / Screen B12
Date/Time   June 16, 2018, 13:30 - 14:15 CEST
#EPR1007  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer's disease.

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Room   Session EPR101 / Screen A1
Date/Time   June 16, 2018, 13:30 - 14:15 CEST

International Congress on Neuromuscular Diseases (ICNMD)
July 6-10, 2018 in Vienna, Austria

Two Posters

#545   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   T. Prukop et al.
Room   Mezzanine Floor Gallery and Foyers
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST
#728  

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures.

Authors   N. Cholet et al.
Room   Session Room 1
Date/Time   July 8, 2018, 5:15pm - 6:30pm CEST

Innovations and State of the Art In Dementia Research meeting (ISADR)
July 16-18, 2081 in Valencia, Spain

Two Oral Communications

   

Cmax-based synergistic therapeutic effect on cognitive disability in mild Alzheimer’s
disease after 36 weeks treatment with baclofen and acamprosate.

Presenter:   Prof Jacques Touchon, MD, PhD, Faculteì de Meìdecine de Montpellier, France
Date/Time   July 16, 2018, 11:35am - 11:55am CEST
    A potential tri-therapy for Alzheimer’s disease.
Presenter:   Dr Rodolphe Hajj, PhD, Chief Pharmacology Officer, Pharnext, France
Date/Time   July 16, 2018, 12:55pm - 1:15pm CEST

Peripheral Nerve Society (PNS) congress
July 22-25, 2018 in Baltimore, US

One Oral Communication

   

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A).

Presenter:   Dr René Goedkoop, MD, Chief Medical Officer, Pharnext, France
Date/Time   July 23, 2018, 2.45pm - 3.00pm EST

Four Posters

#20   Baclofen, naltrexone and sorbitol all contribute to the efficacy of PXT3003 in CMT1A rats.
Authors   R. Hajj et al.
Session   Session 1
Date/Time   July 22, 2018
#45  

Status of the Pivotal Phase III Study of PXT3003 for Charcot-Marie-Tooth Type 1A disease
(CMT1A)

Authors   R. Goedkoop et al.
Session   Session 2
Date/Time   July 23, 2018
#85  

Synergy of baclofen, naltrexone and sorbitol (PXT3003) in Charcot-Marie-Tooth Type 1A
(CMT1A)

Authors   J. Laffaire et al
Session   Session 2
Date/Time   July 23, 2018
#1

Baclofen, naltrexone and sorbitol all contribute to PXT3003-induced myelination in CMT1A
DRG co-cultures

Authors R. Hajj et al.
Session Session 3
Date/Time July 24, 2018

Alzheimer's Association International Conference (AAIC)
July 22-26, 2018 in Chicago, US

Two Posters

#P1-061  

Double-blind argument for a synergistic therapeutic effect of a fixed low-dose combination
of acamprosate and baclofen in Alzheimer’s Disease

Authors   J-M Orgogozo et al
Session   Session P1-01 / Hall F1
Date/Time   July 22, 2018, 9:30am - 4:15pm EST
#P3-042  

PXT864 combination restores cognitive deficits of Alzheimer’s mice, even in animals with
advanced disease that lost responsiveness to donepezil.

Authors   A. Brureau et al.
Session   Session P3-02, Hall F1
Date/Time   July 24, 2018, 9:30am - 4:15pm EST

If you are interested in meeting the Pharnext team during either of these events or if you need more information about Pharnext’s participation, please send an email to contact@pharnext.com

About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit http://www.pharnext.com/

Contact information

Pharnext
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
contact@pharnext.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Media Relations (Europe)
Ulysse Communication
Bruno Arabian, +33 (0)1 81 70 96 30
barabian@ulysse-communication.com
or
Media Relations (U.S.)
RooneyPartners
Kate L. Barrette, +1 212 223 0561
kbarrette@rooneyco.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Proteus Digital Health® Founder to Present at World Economic Forum in Davos21.1.2019 21:54Tiedote

Proteus Digital Health® announced today that Andrew Thompson, its President, Chief Executive Officer and Co-Founder, will present on the progress of Proteus’ digital medicines to improve patient treatment and outcomes at the 2019 World Economic Forum Annual Meeting in Davos-Klosters, Switzerland. Mr. Thompson will present on the official programme: With leaders from financial and academic institutions to address “Theory of the Firm in a World of Digital Ecosystems,” on Tuesday, January 22 beginning at 9:45 a.m. CET in the Congress Centre, Jakobshorn; and Joining state and religious leaders in the Open Forum “Bridging Science with Society,” scheduled to begin at 9:00 a.m. CET on Friday, January 25 at the Swiss Alpine High School Auditorium. This session will be live-streamed on TopLink and the Forum website. Mr. Thompson will also present at two other events during the World Economic Forum Meeting: January 22 at 8:05 p.m., Polish House: Mr. Thompson will provide a keynote address on the

CNIM Is to Equip the French Navy with 14 New Standard Amphibious Landing Craft (EDA-S)21.1.2019 21:36Tiedote

CNIM - in partnership with Socarenam, Mauric and CNN MCO - has been awarded the contract to replace the French Navy's landing crafts. Fourteen new Standard Amphibious Landing Crafts (EDA-S) are to be built over a ten-year period. This contract reasserts CNIM's status as a key partner to the French Navy and a European leader in the area of amphibious operations, supplying the complementary innovative vessels: EDA-S and EDA-R (already in service in the French Navy, designed by CNIM). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005420/en/ CNIM is to equip the French Navy with 14 new Standard Amphibious Landing Craft (EDA-S) - (c) CNIM Next-generation of vessels designed by CNIM "Winning this European tender reasserts CNIM's status as experts in amphibious craft design. CNIM is to replace the French Navy's existing landing craft with fourteen new Standard Amphibious Landing Craft, also called EDA-S", notes Philippe Demi

Naspers Progresses Plans to List MultiChoice Group Limited and Unbundle Its Shares in MultiChoice Group to Naspers Shareholders21.1.2019 19:04Tiedote

On 17 September 2018, Naspers Limited (JSE: NPN; LSE: NPSN) announced its intention to list its video entertainment business separately on the Johannesburg Stock Exchange (JSE) as MultiChoice Group Limited (MultiChoice Group) and simultaneously unbundle its shares in this business to Naspers shareholders. It is expected that the Admission and dealings in the Shares will commence on Wednesday, 27 February 2019. In relation to the Admission, MultiChoice Group today published a pre-listing statement compliant with the requirements of the JSE. MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax and Irdeto and their subsidiaries and affiliates, will, among others, be subsidiaries of MultiChoice Group. MultiChoice Group is the leading video entertainment operator on the African continent, with an extensive local and international content offering. It is one of the fastest-growing pay-TV broadcast providers globally and provides entertainment to around 14 million households across 50

MultiChoice Group Limited (MCG) Today Released Its Pre-Listing Statement in Compliance with the JSE Listings Requirements21.1.2019 18:59Tiedote

Naspers Limited (JSE: NPN; LSE: NPSN) : MultiChoice Group Limited (MCG) today released its pre-listing statement in compliance with the JSE Listings Requirements (www.multichoice.com) providing further details about its listing on the Johannesburg Stock Exchange (JSE). Trading in MCG shares is expected to commence on the JSE on Wednesday, 27 February 2019. As announced on 17 September 2018, MCG will include, amongst others, MultiChoice South Africa (MCSA), MultiChoice Africa, Showmax, as well as the global digital platform security provider, Irdeto and all their subsidiaries and affiliates (“the Group”). Calvo Mawela, Group Chief Executive Officer of MCG said: “We believe the listing of MultiChoice provides an excellent opportunity to invest in the leading provider of video entertainment on the African continent. MCG brings an incomparable local and international content offering to around 14-million households and is one of the fastest growing pay-TV broadcast providers globally. With

ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.21.1.2019 17:05Tiedote

ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first top-of-head-connected nasal CPAP mask, across the United States, with a newly designed nasal cradle cushion that sits just under the wearer’s nose. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005035/en/ AirFit N30i nasal CPAP mask, front view (Photo: Business Wire) The top-of-head connection keeps tubing out of the wearer’s way, letting them move and sleep in any position. The nasal cradle cushion – ResMed’s first – is designed to reduce facial markings and irritation. AirFit N30i is also convenient for equipment providers and sleep labs – it fits 96 percent of PAP users with just two frame sizes and four cushion sizes. How AirFit N30i compares to the market-leading nasal top-of-head mask In side-by-side comparisons, three out of four users preferred AirFit N30i over the other nasal mask with a top-of-head connection. A majority stated they loved

Metabolon Appoints Michael Rasche as President of International Business21.1.2019 16:06Tiedote

Metabolon, the world leader in metabolomics, today announced that Michael Rasche joined the company as President of International Business. Michael will report to Rohan Hastie, Metabolon’s President and CEO, and become a member of the corporate executive team. He will lead all of Metabolon's international business activities with a strong focus on customer and team expansion. "We are thrilled to have Michael join the Metabolon team," said Hastie. "Michael brings a wealth of commercial and business experience across multiple areas of life sciences, from Pharma to Diagnostics and Biotech. I know he will make an immediate impact on our existing and future customers." "I am very excited to become part of the Metabolon success story," added Rasche. "I will passionately lead our team to drive accelerated business expansion across all international markets. Our Precision Metabolomics™ technology is delivering biomarker discoveries, innovative diagnostic tests, and groundbreaking data in genom

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme